Eli Lilly has entered into an artificial intelligence (AI) drug discovery collaboration with XtalPi, which is worth up to US$250 M and will provide Lilly with access to XtalPi’s ID4Inno™ drug discovery platform to design and deliver drug candidates for an undisclosed target. For XtalPi, the deal with Lilly is its largest deal to date by total deal value and validates the company’s expertise in AI driven drug discovery and development.